Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Chem Biodivers ; 20(1): e202200843, 2023 Jan.
Article in English | MEDLINE | ID: mdl-36574472

ABSTRACT

Golden Camellias have recently been used as a food, cosmetic, and traditional medicine in China and Vietnam. Forty-two species have natural distribution in Vietnam, of which thirty-two species were considered endemic species of this country. The morphology of leaves and flowers of these species were similar; therefore, their taxonomic identification usually needed experts and the authentication has often been confused among species. Our study aims to describe the genetic diversity and the relationship of six species Camellia phanii, Camellia tamdaoensis, Camellia tienii, Camellia flava, Camellia petelotii and Camellia euphlebia by using three chloroplast DNA-barcodes: matK, rbcL and trnH-psbA. We also clarified the significant differences in anatomical characteristics of midvein and blade of their leaves, which suggested the possibility to use these criteria in taxonomy. In addition, preliminary chemical profiles of the methanolic extracts of leaves from six Golden Camellias such as total phenolic content (TPC), total flavonoid content (TFC), total anthocyanin content (TAC) and chlorogenic acids content (TCGAs) also showed the diversity among them. Interestingly, the discrimination on the catechins profile among six species followed the same tendency with the genetic distance on the phylogeny tree suggesting that catechins (i. e., discriminative catechins) can be biomarkers for the chemotaxonomy of these six Golden Camellias.


Subject(s)
Camellia , Camellia/chemistry , Vietnam , Flavonoids/analysis , Flowers/chemistry , Plant Leaves , DNA Barcoding, Taxonomic , Phylogeny , DNA, Plant/analysis
2.
Braz J Biol ; 84: e264369, 2022.
Article in English | MEDLINE | ID: mdl-36287528

ABSTRACT

Panax vietnamensis Ha et Grushv. is a precious medicinal species native to the tropical forests of Vietnam. Due to habitat loss and over-harvesting, this species is endangered in Vietnam. To conserve the species, we investigated genetic variability and population structure using nine microsatellites for 148 individuals from seven populations across the current distribution range of P. vietnamensis in Vietnam. We determined a moderate genetic diversity within populations (HO = 0.367, HE = 0.437) and relatively low population differentiation (the Weir and Cockerham index of 0.172 and the Hedrick index of 0.254) and showed significant differentiation (P < 0.05), which suggested fragmented habitats, over-utilization and over-harvesting of P. vietnamensis. Different clustering methods revealed that individuals were grouped into two major clusters, which were associated with gene flow across the geographical range of P. vietnamensis. This study also detected that ginseng populations can have undergone a recent bottleneck. We recommend measures in future P. vietnamensis conservation and breeding programs.


Subject(s)
Panax , Humans , Panax/genetics , Panax/chemistry , Vietnam , Plant Breeding , Microsatellite Repeats/genetics , Asian People , Genetic Variation/genetics
3.
Chemosphere ; 306: 135474, 2022 Nov.
Article in English | MEDLINE | ID: mdl-35760139

ABSTRACT

Green synthesis has emerged as a sustainable approach for the fabrication of nanomaterials in the last few decades. Leaf extracts have been considered low-cost and highly efficient reactants for the synthesis of nanoparticles. In this study, an aqueous extract of Cleistocalyx operculatus leaves was employed as a reductant to synthesize Ag/TiO2 nanocomposites. The morphology, structure, and interface interaction of the Ag/TiO2 nanocomposites were investigated by (i) X-ray diffraction (XRD) to determine the crystallinity, (ii) scanning electron microscopy (SEM) to determine the morphologies, (iii) energy dispersive X-ray spectroscopy (EDX) to determine the elemental composition and distribution, and (iv) diffuse reflectance spectroscopy (DRS) to understand the optical properties. The results showed that Ag nanoparticles (AgNPs) with particle sizes of 20-40 nm homogeneously covered the surface of the TiO2 nanoparticles. The green-synthesized Ag/TiO2 nanocomposite also exhibited an excellent photodegradation ability for Rhodamine B with a removal percentage up to 91.4% after 180 min of photocatalytic reaction.


Subject(s)
Metal Nanoparticles , Nanocomposites , Syzygium , Catalysis , Coloring Agents , Metal Nanoparticles/chemistry , Nanocomposites/chemistry , Plant Extracts/chemistry , Silver/chemistry , Titanium/chemistry
4.
Z Rheumatol ; 80(3): 263-269, 2021 Apr.
Article in German | MEDLINE | ID: mdl-33355702

ABSTRACT

Rheumatic diseases can lead to a state of malnutrition via a variety of mechanisms. Malnutrition is defined as an insufficient availability of energy, proteins, electrolytes and other nutrients compared to the requirements of a healthy body. After such a catabolic phase, a sudden resupply of the body's full caloric needs can cause life-threatening complications due to an acute paucity of electrolytes and micronutrients. Such metabolic disturbances occurring after the reconstitution of nutrition are termed refeeding syndrome. With sufficient background knowledge about the refeeding syndrome, physicians can prevent serious complications for patients through an adequate reconstitution of caloric intake, the monitoring of relevant laboratory parameters and the supplementation of deficient electrolytes and micronutrients. This review aims to explain the pathological mechanisms driving the refeeding syndrome, to identify risk factors for developing a refeeding syndrome especially in patients with rheumatic diseases and to present strategies to prevent the occurrence of the refeeding syndrome during nutrient reconstitution.


Subject(s)
Malnutrition , Refeeding Syndrome , Electrolytes , Humans , Malnutrition/diagnosis , Malnutrition/etiology , Malnutrition/prevention & control , Refeeding Syndrome/diagnosis , Refeeding Syndrome/prevention & control , Risk Factors
5.
Bioresour Technol ; 256: 491-501, 2018 May.
Article in English | MEDLINE | ID: mdl-29472123

ABSTRACT

Algae is a well-known organism that its characteristic is prominent for biofuel production and wastewater remediation. This critical review aims to present the applicability of algae with in-depth discussion regarding three key aspects: (i) characterization of algae for its applications; (ii) the technical approaches and their strengths and drawbacks; and (iii) future perspectives of algae-based technologies. The process optimization and combinations with other chemical and biological processes have generated efficiency, in which bio-oil yield is up to 41.1%. Through life cycle assessment, algae bio-energy achieves high energy return than fossil fuel. Thus, the algae-based technologies can reasonably be considered as green approaches. Although selling price of algae bio-oil is still high (about $2 L-1) compared to fossil fuel's price of $1 L-1, it is expected that the algae bio-oil's price will become acceptable in the next coming decades and potentially dominate 75% of the market.


Subject(s)
Biofuels , Wastewater , Plant Oils , Polyphenols
6.
Vaccine ; 36(51): 7901-7905, 2018 12 14.
Article in English | MEDLINE | ID: mdl-29478753

ABSTRACT

In some settings, rotavirus vaccines have been associated with a low-level risk of intussusception, the most common cause of bowel obstruction in infants. As Vietnam prepares to introduce rotavirus vaccine into the national immunization program, we sought to better characterize the epidemiology of recurrent intussusception. We enrolled children <2 years of age who were hospitalized for intussusception retrospectively from January 2013 through December 2014 and prospectively from January 2015 through December 2016 at 2 hospitals in Vietnam. We enrolled 2477 children. Nearly all children were successfully treated by enema with low surgery rate (1%). We found 10% of children (n = 254) experienced at least once recurrence (range: 1-6) and 57% of first recurrences happened within the first 12 weeks after treatment of the first episode. The median age at first intussusception was 13 months for children without a recurrent episode and 10 months for children with a recurrence. The symptoms of the recurrent cases were milder with less vomiting (67%), bloody stool (7%) and fever (10%) compared to the initial cases (p < 0.01). We found the rate of recurrences following enema reduction of intussusception to be similar to that reported from other countries. Due to the high rate of intussusception and recurrent episodes in Vietnam, a better understanding of the cause of recurrent intussusception will be critical in assessing intussusception cases after rotavirus introduction.


Subject(s)
Hospitalization/statistics & numerical data , Intussusception/epidemiology , Enema , Female , Fever/epidemiology , Humans , Infant , Infant, Newborn , Intussusception/therapy , Male , Population Surveillance , Prospective Studies , Recurrence , Retrospective Studies , Rotavirus Infections/prevention & control , Rotavirus Vaccines/adverse effects , Vietnam/epidemiology
7.
Prostate Cancer Prostatic Dis ; 20(2): 186-192, 2017 06.
Article in English | MEDLINE | ID: mdl-28117383

ABSTRACT

BACKGROUND: We examined the ability of a biopsy-based 22-marker genomic classifier (GC) to predict for distant metastases after radiation and a median of 6 months of androgen deprivation therapy (ADT). METHODS: We studied 100 patients with intermediate-risk (55%) and high-risk (45%) prostate cancer who received definitive radiation plus a median of 6 months of ADT (range 3-39 months) from 2001-2013 at a single center and had available biopsy tissue. Six to ten 4 micron sections of the needle biopsy core with the highest Gleason score and percentage of tumor involvement were macrodissected for RNA extraction. GC scores (range, 0.04-0.92) were determined. The primary end point of the study was time to distant metastasis. Median follow-up was 5.1 years. There were 18 metastases during the study period. RESULTS: On univariable analysis (UVA), each 0.1 unit increase in GC score was significantly associated with time to distant metastasis (hazard ratio: 1.40 (1.10-1.84), P=0.006) and remained significant after adjusting for clinical variables on multivariable analysis (MVA) (adjusted hazard ratio: 1.36 (1.04-1.83), P=0.024). The c-index for 5-year distant metastasis was 0.45 (95% confidence interval: 0.27-0.64) for Cancer of the Prostate Risk Assessment score, 0.63 (0.40-0.78) for National Comprehensive Cancer Network (NCCN) risk groups, and 0.76 (0.57-0.89) for the GC score. Using pre-specified GC risk categories, the cumulative incidence of metastasis for GC>0.6 reached 20% at 5 years after radiation (P=0.02). CONCLUSIONS: We believe this is the first demonstration of the ability of the biopsy-based GC score to predict for distant metastases after definitive radiation and ADT for intermediate- and high-risk prostate cancer. Patients with the highest GC risk (GC>0.6) had high rates of metastasis despite multi-modal therapy suggesting that they could potentially be candidates for treatment intensification and/or enrollment in clinical trials of novel therapy.


Subject(s)
Genomics , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/radiotherapy , Risk Assessment , Aged , Androgen Antagonists/administration & dosage , Androgens/genetics , Biopsy, Needle , Combined Modality Therapy , Humans , Male , Middle Aged , Neoplasm Grading , Neoplasm Metastasis , Proportional Hazards Models , Prostate/pathology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Radiotherapy Dosage , Risk Factors
8.
J Mal Vasc ; 37(6): 300-10, 2012 Dec.
Article in French | MEDLINE | ID: mdl-23122646

ABSTRACT

Rivaroxaban is a direct oral anticoagulant targeting factor Xa. Efficacy and safety of rivaroxaban were evaluated through the phase 3 EINSTEIN program, consisting in three clinical trials regarding the treatment of deep vein thrombosis (EINSTEIN DVT), pulmonary embolism (EINSTEIN PE), and in secondary prevention after a first episode of venous thromboembolic disease (EISNTEIN EXT). Rivaroxaban was recently approved both by the European and the French Health agencies for the treatment of DVT and prevention of deep vein thrombosis recurrence. This report addresses the use of rivaroxaban in clinical practice in such indications.


Subject(s)
Anticoagulants/therapeutic use , Morpholines/therapeutic use , Pulmonary Embolism/drug therapy , Thiophenes/therapeutic use , Venous Thromboembolism/drug therapy , Venous Thrombosis/drug therapy , Age Factors , Drug Interactions , Factor Xa , France , Hemorrhage/chemically induced , Humans , Morpholines/adverse effects , Morpholines/pharmacology , Risk Factors , Rivaroxaban , Thiophenes/adverse effects , Thiophenes/pharmacology , Vitamins/antagonists & inhibitors
9.
Article in English | WPRIM | ID: wpr-14745

ABSTRACT

Rhinitis is a global problem and is defined as the presence of at least one of the following: congestion, rhinorrhea, sneezing, nasal itching, and nasal obstruction. The two major classifications are allergic and nonallergic rhinitis (NAR). Allergic rhinitis occurs when an allergen is the trigger for the nasal symptoms. NAR is when obstruction and rhinorrhea occurs in relation to nonallergic, noninfectious triggers such as change in the weather, exposure to caustic odors or cigarette smoke, barometric pressure differences, etc. There is a lack of concomitant allergic disease, determined by negative skin prick test for relevant allergens and/or negative allergen-specific antibody tests. Both are highly prevalent diseases that have a significant economic burden on society and negative impact on patient quality of life. Treatment of allergic rhinitis includes allergen avoidance, antihistamines (oral and intranasal), intranasal corticosteroids, intranasal cromones, leukotriene receptor antagonists, and immunotherapy. Occasional systemic corticosteroids and decongestants (oral and topical) are also used. NAR has 8 major subtypes which includes nonallergic rhinopathy (previously known as vasomotor rhinitis), nonallergic rhinitis with eosinophilia, atrophic rhinitis, senile rhinitis, gustatory rhinitis, drug-induced rhinitis, hormonal-induced rhinitis, and cerebral spinal fluid leak. The mainstay of treatment for NAR are intranasal corticosteroids. Topical antihistamines have also been found to be efficacious. Topical anticholinergics such as ipratropium bromide (0.03%) nasal spray are effective in treating rhinorrhea symptoms. Adjunct therapy includes decongestants and nasal saline. Investigational therapies in the treatment of NAR discussed include capsaicin, silver nitrate, and acupuncture.


Subject(s)
Humans , Acupuncture , Adrenal Cortex Hormones , Allergens , Capsaicin , Cholinergic Antagonists , Eosinophilia , Estrogens, Conjugated (USP) , Histamine Antagonists , Immunotherapy , Ipratropium , Leukotriene Antagonists , Nasal Decongestants , Nasal Obstruction , Odorants , Pruritus , Quality of Life , Rhinitis , Rhinitis, Allergic, Perennial , Rhinitis, Atrophic , Silver Nitrate , Skin , Smoke , Sneezing , Therapies, Investigational , Tobacco Products , Weather
10.
J Obstet Gynaecol ; 29(7): 594-8, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19757261

ABSTRACT

Prenatal multivitamin supplements (PMS) are recommended during pregnancy. Suboptimal adherence in women experiencing gastrointestinal (GI) conditions is thought to be attributed to the high elemental iron content in PMS. This study sought to quantify adherence and tolerability of iron-containing PMS in women with pre-existing GI conditions by recruiting women who called the Motherisk Helpline. Women with (n = 36) and without (n = 166) pre-existing GI conditions were randomised to either PregVit (n = 106) or Orifer F (n = 96). Monthly follow-up interviews were conducted to assess pill intake and GI adverse effects associated with PMS. The results of our study suggest that with the use of small size and low dose iron PMS, women with pre-existing GI conditions do not experience (1) more GI adverse effects, (2) lower adherence than women with no such conditions, and (3) may experience less severe nausea and vomiting of pregnancy. Supplementing with small tablets of low dose iron PMS should be considered.


Subject(s)
Gastrointestinal Diseases , Iron/administration & dosage , Medication Adherence , Pregnancy Complications , Trace Elements/administration & dosage , Dietary Supplements , Female , Humans , Pregnancy , Prenatal Care
11.
Eur J Clin Invest ; 36(4): 224-30, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16620283

ABSTRACT

BACKGROUND: The mechanisms involved in the decline of high-density lipoprotein (HDL) levels at a higher dose of atorvastatin have not yet been elucidated. We investigated the effects of atorvastatin on HDL-apolipoprotein (apo) A-I metabolism in dogs, a species lacking cholesteryl ester transfer protein activity. MATERIALS AND METHODS: Seven ovariectomized normolipidaemic female Beagle dogs underwent a primed constant infusion of [5,5,5-(2)H(3)] leucine to determine HDL-apo A-I kinetics before and after atorvastatin treatment (5 mg kg(-1) d(-1) for 6 weeks). Plasma lipoprotein profiles, activity of HDL-modifying enzymes involved in reverse cholesterol transport and hepatic scavenger receptor class B type I (SR-BI) expression were also studied. RESULTS: Atorvastatin treatment decreased HDL-cholesterol levels (3.56 +/- 0.24 vs. 2.64 +/- 0.15 mmol L(-1), P < 0.05). HDL-triglycerides were not affected. HDL-phospholipids levels were decreased (4.28 +/- 0.13 vs. 3.29 +/- 0.13 mmol L(-1), P < 0.05), as well as phospholipids transfer protein (PLTP) activity (0.83 +/- 0.05 vs. 0.60 +/- 0.05 pmol microL(-1) min(-1), P < 0.05). Activity of lecithin: cholesterol acyl transferase (LCAT), hepatic lipase (HL) and SR-BI expression did not change. HDL-apo A-I absolute production rate (APR) was higher after treatment (twofold, P < 0.05) as well as fractional catabolic rate (FCR) (threefold, P < 0.05). This resulted in lower HDL-apo A-I levels (2.36 +/- 0.03 vs. 1.55 +/- 0.04 g l(-1), P < 0.05). Plasma lipoprotein profiles showed a decrease in large HDL(1) levels, with lower apo A-I and higher apo E levels in this subfraction. CONCLUSIONS: Although a high dose of atorvastatin up-regulated HDL-apo A-I production, this drug also increased HDL-apo A-I FCR in dogs. This effect could be explained by a higher uptake of apo E-enriched HDL(1) by hepatic lipoprotein receptors.


Subject(s)
Anticholesteremic Agents/pharmacology , Apolipoprotein A-I/metabolism , Cholesterol, HDL/analysis , Dogs/metabolism , Heptanoic Acids/pharmacology , Pyrroles/pharmacology , Animals , Atorvastatin , Chromatography, Liquid/methods , Female , Immunoblotting/methods , Lipase/analysis , Liver/chemistry , Ovariectomy , Phospholipid Transfer Proteins/blood , Phospholipids/blood , Scavenger Receptors, Class B/metabolism , Triglycerides/blood
12.
Arthritis Rheum ; 42(10): 2060-73, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10524677

ABSTRACT

OBJECTIVE: To noninvasively examine the pathogenesis of rat adjuvant-induced arthritis (AIA) by magnetic resonance imaging (MRI), and to correlate MRI indices of disease progression with classic inflammatory parameters and histologic evaluation. METHODS: AIA was established in male Lewis rats following subcutaneous injection in the right hindpaw with 0.5 mg of heat-killed Mycobacterium butyricum suspended in light mineral oil. In vivo MRI evaluations of soft tissue and bony changes in AIA rats with matched histopathology were correlated with changes in left hindpaw volumes, circulating leukocytes, acute-phase reactants, and urinary collagen crosslinks throughout the disease process. RESULTS: MRI of arthritic tibiotarsal joints of the uninjected left hindpaws from AIA rats demonstrated 2 distinct phases of disease activity. The first phase, apparent between days 10 and 18, was characterized by periarticular inflammation with marked synovitis, synovial fibroplasia, and distension of the joint capsule into the surrounding tissue. The secondary phase, occurring between days 18 and 30, was marked by continued soft tissue inflammation, periostitis with osteolysis, and periosteal new bone formation progressing to a state of near complete ankylosis by day 30. These 2 phases of disease activity observed by MRI paralleled biochemical, cellular, and histologic markers of disease progression. CONCLUSION: MRI can be used to noninvasively detect, monitor, and quantify the chronic synovitis and progressive destruction of soft tissue and bone in live AIA rats, thereby improving the ability to evaluate disease progression in this preclinical animal model of rheumatoid arthritis.


Subject(s)
Arthritis, Experimental/diagnostic imaging , Magnetic Resonance Imaging , Animals , Arthritis, Experimental/immunology , Arthritis, Experimental/pathology , Arthritis, Experimental/physiopathology , Disease Models, Animal , Inflammation/diagnostic imaging , Male , Prognosis , Radiography , Rats , Rats, Inbred Lew
13.
J Hypertens ; 16(11): 1357-69, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9856375

ABSTRACT

OBJECTIVE: To compare the acute and chronic effects of nifedipine retard (NPA), nifedipine gastrointestinal therapeutic system (NGITS) and amlodipine at trough and peak plasma concentrations of drug on blood pressure and heart rate, and on plasma norepinephrine and epinephrine levels in patients with mild-to-moderate hypertension (diastolic blood pressure 95-115 mmHg). DESIGN AND METHODS: After 3-4 weeks' placebo treatment, patients of both sexes were randomly allocated to be administered 10 or 20 mg NPA twice a day, 30 or 60 mg NGITS once a day, and 5 or 10 mg amlodipine once a day for 6 weeks. Initially, for the first 2 weeks, the lowest dose of each drug was used, but higher doses were administered after 2 weeks if sitting diastolic blood pressure was > 90 mmHg. Patients were evaluated after administration of the first dose and after 6 weeks' therapy in a hospital setting. Blood samples were taken for high-performance liquid chromatography measurement of catecholamine and drug levels at various intervals for a period covering trough to peak drug level ranges. RESULTS: Administration of all three drugs reduced clinic blood pressure to the same level after 6 weeks' therapy, but heart rate was increased slightly only with amlodipine (P < 0.05). Administration of NPA reduced blood pressure more abruptly whereas administrations of NGITS and amlodipine induced smoother falls after acute and chronic treatments: a significant increase in heart rate was observed with amlodipine after chronic treatment. Both acute and chronic treatments with NPA (n = 19) increased norepinephrine levels (P < 0.01) transiently (2-4 h). In contrast, administration of NGITS (n = 22) did not increase norepinephrine levels and even induced a slight but significant decrease in norepinephrine levels 5-6 h after chronic treatments. Although administration of amlodipine (n = 22) did not increase norepinephrine levels transiently either after acute or after chronic administration, it did induce a sustained rise in basal norepinephrine levels by more than 50% after chronic therapy (P < 0.01). Plasma epinephrine levels were not increased by any of the treatments and even a slight decrease was observed 4 h after administration of a dose following chronic treatments with NGITS and amlodipine (P < 0.05). CONCLUSIONS: The transient increase in norepinephrine levels observed with NPA and the sustained increases in norepinephrine levels observed after chronic treatment with amlodipine suggest that sympathetic activation occurs with those two drugs. The lack of increase in norepinephrine levels after administration of NGITS suggests that this formulation does not activate the sympathetic system. The lowering of epinephrine levels after administrations of NGITS and amlodipine suggests that inhibition of release of epinephrine by the adrenal medulla occurs with longer-acting dihydropyridine formulations.


Subject(s)
Amlodipine/therapeutic use , Epinephrine/blood , Hypertension/drug therapy , Nifedipine/therapeutic use , Norepinephrine/blood , Vasodilator Agents/therapeutic use , Adult , Amlodipine/administration & dosage , Antihypertensive Agents/administration & dosage , Antihypertensive Agents/therapeutic use , Blood Pressure/drug effects , Diastole , Drug Administration Schedule , Female , Heart Rate/drug effects , Humans , Hypertension/blood , Hypertension/physiopathology , Male , Middle Aged , Nifedipine/administration & dosage , Single-Blind Method , Systole , Vasodilator Agents/administration & dosage
14.
J Hypertens ; 16(9): 1357-69, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9746123

ABSTRACT

OBJECTIVE: To compare the acute and chronic effects of nifedipine retard (NPA), nifedipine gastrointestinal therapeutic system (NGITS) and amlodipine at trough and peak plasma concentrations of drug on blood pressure and heart rate, and on plasma norepinephrine and epinephrine levels in patients with mild-to-moderate hypertension (diastolic blood pressure 95-115 mmHg). DESIGN AND METHODS: After 3-4 weeks' placebo treatment, patients of both sexes were randomly allocated to be administered 10 or 20 mg NPA twice a day, 30 or 60 mg NGITS once a day, and 5 or 10 mg amlodipine once a day for 6 weeks. Initially, for the first 2 weeks, the lowest dose of each drug was used, but higher doses were administered after 2 weeks if sitting diastolic blood pressure was > 90 mmHg. Patients were evaluated after administration of the first dose and after 6 weeks' therapy in a hospital setting. Blood samples were taken for high-performance liquid chromatography measurement of catecholamine and drug levels at various intervals for a period covering trough to peak drug level ranges. RESULTS: Administration of all three drugs reduced clinic blood pressure to the same level after 6 weeks' therapy, but heart rate was increased slightly only with amlodipine (P < 0.05). Administration of NPA reduced blood pressure more abruptly whereas administrations of NGITS and amlodipine induced smoother falls after acute and chronic treatments: a significant increase in heart rate was observed with amlodipine after chronic treatment. Both acute and chronic treatments with NPA (n = 19) increased norepinephrine levels (P < 0.01) transiently (2-4 h). In contrast, administration of NGITS (n = 22) did not increase norepinephrine levels and even induced a slight but significant decrease in norepinephrine levels 5-6 h after chronic treatments. Although administration of amlodipine (n = 22) did not increase norepinephrine levels transiently either after acute or after chronic administration, it did induce a sustained rise in basal norepinephrine levels by more than 50% after chronic therapy (P < 0.01). Plasma epinephrine levels were not increased by any of the treatments and even a slight decrease was observed 4 h after administration of a dose following chronic treatments with NGITS and amlodipine (P < 0.05). CONCLUSIONS: The transient increase in norepinephrine levels observed with NPA and the sustained increases in norepinephrine levels observed after chronic treatment with amlodipine suggest that sympathetic activation occurs with those two drugs. The lack of increase in norepinephrine levels after administration of NGITS suggests that this formulation does not activate the sympathetic system. The lowering of epinephrine levels after administrations of NGITS and amlodipine suggests that inhibition of release of epinephrine by the adrenal medulla occurs with longer-acting dihydropyridine formulations.


Subject(s)
Amlodipine/therapeutic use , Antihypertensive Agents/therapeutic use , Epinephrine/blood , Hypertension/blood , Hypertension/drug therapy , Nifedipine/therapeutic use , Norepinephrine/blood , Vasodilator Agents/therapeutic use , Adult , Blood Pressure/drug effects , Drug Administration Schedule , Female , Heart Rate/drug effects , Humans , Hypertension/physiopathology , Male , Middle Aged , Nifedipine/administration & dosage , Time Factors
15.
Crit Care Med ; 24(5): 827-34, 1996 May.
Article in English | MEDLINE | ID: mdl-8706461

ABSTRACT

OBJECTIVES: To determine whether changes in cardiac output, regional blood flow, and intracranial pressure during permissive hypercapnia are blood pH-dependent and can be attenuated by correction of intravascular acidemia. DESIGN: Prospective, controlled study. SETTING: Research laboratory. SUBJECTS: Female Marino ewes. INTERVENTIONS: Animals were instrumented with a pulmonary artery catheter, femoral arterial and venous catheters, a catheter in the third cerebral ventricle, and ultrasonic flow probes on the left carotid, superior mesenteric, and left renal arteries 1 wk before experimentation. At initiation of the protocol, ewes underwent endotracheal intubation and mechanical ventilation under general anesthesia. Minute ventilation was reduced to induce hypercapnia with a target PaCO2 of 80 torr (10.7 kPa). In the pH-uncorrected group (n = 6), arterial blood pH was allowed to decreased without treatment. In the pH-corrected group (n = 5), 14.4 mEq/kg of sodium bicarbonate was given intravenously as a bolus to correct arterial blood pH toward a target arterial pH of 7.40 (dose calculated by the Henderson-Hasselbalch equation). MEASUREMENTS AND MAIN RESULTS: Arterial blood pH, PCO2, cardiac output, intracranial pressure, and carotid, superior mesenteric, and renal artery blood flow rates were measured at normocapnic baseline and at every hour during hypercapnia for 6 hrs. In the pH-uncorrected group, arterial blood pH decreased from 7.41 +/- 0.03 at normocapnia to 7.14 +/- 0.01 (p < .01 vs. normocapnia) as blood PCO2 increased to 81.2 +/- 1.8 torr (10.8 +/- 0.2 kPa). In the pH-corrected group, arterial blood pH was 7.42 +/- 0.02 at normocapnia and was maintained at 7.37 +/- 0.01 while PaCO2 was increased to 80.3 +/- 0.9 torr (10.7 +/- 0.1 kPa). Significant increases in cardiac output occurred with the initiation of hypercapnia for both groups (pH-uncorrected group: 4.3 +/- 0.6 L/min at normocapnia vs. 6.8 +/- 1.0 L/min at 1 hr [p < .05]; pH-corrected group: 4.1 +/- 0.4 at normocapnia vs. 5.7 +/- 0.4 L/min at 1 hr [p < .05]). However, this increase was sustained only in the uncorrected group. Changes in carotid and mesenteric artery blood flow rates, as a percent of baseline values, showed sustained significant increases in the pH-uncorrected groups (p < .05) and only transient (carotid at 1 hr) or no (superior mesenteric) significant change in the pH-corrected groups. Conversely, significant increases in renal artery blood flow were seen only in the pH-uncorrected group during the last 2 hrs of the experiment (p < .05). Organ blood flow, as a percent of cardiac output, did not change significantly in either group. Intracranial pressure increased significantly in the pH-uncorrected group (9.0 +/- 1.5 mm Hg at normocapnia vs. 26.8 +/- 5.1 at 1 hr, p < .05), and remained increased, while showing no significant change in the pH-corrected group (8.5 +/- 1.6 mm Hg at normocapnia to 7.7 +/- 4.2 at 1 hr). CONCLUSIONS: Acute hypercapnia, induced within 1 hr, is associated with significant increases in cardiac output, organ blood flow, and intracranial pressure. These changes can be significantly attenuated by correction of blood pH with the administration of sodium bicarbonate, without adverse effects on hemodynamics.


Subject(s)
Hypercapnia/blood , Positive-Pressure Respiration/adverse effects , Respiratory Distress Syndrome/therapy , Sodium Bicarbonate/therapeutic use , Acute Disease , Animals , Blood Gas Analysis , Disease Models, Animal , Drug Evaluation, Preclinical , Female , Hemodynamics , Hydrogen-Ion Concentration , Hypercapnia/drug therapy , Hypercapnia/etiology , Prospective Studies , Random Allocation , Respiratory Distress Syndrome/physiopathology , Sheep , Time Factors
16.
Am J Trop Med Hyg ; 48(3): 398-402, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8470777

ABSTRACT

In this study, 638 patients with either Plasmodium falciparum or P. vivax malaria were treated with artemisinin (qinghaosu) that was isolated and formulated into tablets and capsules in Vietnam. In all cases, artemisinin treatment resulted in a rapid clearance of parasitemia and fever. Recrudescence rates were highest in those groups receiving treatment for five or less days (50%), but were between 10% and 23% for those groups receiving the drug for 5-10 days. A low recrudescent rate (9.5%) was also found when patients were treated with a combination of artemisinin for three days and tetracycline for five days. Thus, artemisinin represents a useful and economically feasible component of the malaria control program in Vietnam.


Subject(s)
Antimalarials/therapeutic use , Artemisinins , Malaria, Falciparum/drug therapy , Malaria, Vivax/drug therapy , Sesquiterpenes/therapeutic use , Administration, Oral , Adult , Antimalarials/administration & dosage , Capsules , Child , Humans , Retrospective Studies , Sesquiterpenes/administration & dosage , Tablets , Vietnam
18.
Neurosci Lett ; 77(3): 316-20, 1987 Jun 26.
Article in English | MEDLINE | ID: mdl-3614765

ABSTRACT

Using noxious heat-evoked tail flick in rats anesthetized with pentobarbital infusion, we studied the effects of diazepam applied intrathecally. This drug caused a marked suppression of nociceptive reflexes in a dose-dependent manner. In addition, a small non-suppressive dose of diazepam potentiated electroacupuncture effects. These results are discussed in terms of gamma-aminobutyric acid (GABA) since it is known that diazepam enhances binding of GABA to its receptor and hence potentiates inhibitory effects of GABA in the spinal cord. The possible synergism of diazepam and pentobarbital is also discussed.


Subject(s)
Acupuncture Therapy , Diazepam/pharmacology , Pain/prevention & control , Pentobarbital/administration & dosage , Reflex/drug effects , Spinal Cord/physiopathology , Anesthesia, Intravenous , Animals , Diazepam/administration & dosage , Drug Synergism , Humans , Injections, Spinal , Male , Pain/physiopathology , Rats
SELECTION OF CITATIONS
SEARCH DETAIL